甘露醇对开放式腹主动脉瘤修复术结局的影响
本研究基于血管外科学会血管质量倡议数据库2003至2021年数据,回顾性分析15961例开放式腹主动脉瘤修复患者,比较术中应用甘露醇与否的结局。结果显示甘露醇与肾上型钳夹组30天死亡率显著降低相关(HR 0.63,P < .001),但未显著减少肾脏并发症。
要点
- 甘露醇与肾上型钳夹组30天死亡率降低独立相关(HR 0.63)。
- 甘露醇未显著降低两组肾脏并发症发生率。
- 肾上型钳夹患者无论肾小球滤过率状态如何均可能获益。
核心结论
- 术中甘露醇与开放式腹主动脉瘤修复术后生存改善相关,尤其在肾上型钳夹患者中。
- 甘露醇未显著减少肾脏并发症,但可能通过心脏保护作用使特定亚组获益。
研究设计与样本
- 回顾性分析血管外科学会血管质量倡议数据库2003至2021年数据。
- 共纳入15961例开放式腹主动脉瘤修复患者,按术中是否使用甘露醇分组,并按近端钳夹位置(肾上型 vs 肾下型)分层。
- 采用单变量和多变量logistic回归、Kaplan-Meier生存曲线及Cox回归分析,调整年龄、性别、手术紧迫性、吸烟状态、ASA分级、钳夹时间、估计失血量、术前肌酐、充血性心力衰竭史、总手术时间、他汀使用和P2Y受体抑制剂使用等变量。
主要发现
- 8963例(56.2%)术中接受了甘露醇。
- 肾下型钳夹组30天死亡率:甘露醇组5.4% vs 未用组9.6%(P < .001)。
- 肾上型钳夹组30天死亡率:甘露醇组7.3% vs 未用组18.2%(P < .001)。
- 调整分析中,肾上型钳夹组甘露醇与30天死亡率显著降低相关(风险比0.63;P < .001)。
- 甘露醇未显著影响两组肾脏并发症;肾上型钳夹患者无论肾小球滤过率状态如何均观察到生存获益。
临床怎么用
- 可考虑在开放式腹主动脉瘤修复术中选择性使用甘露醇,尤其对肾上型钳夹的高危患者。
- 不应期望甘露醇显著降低肾脏并发症,其主要获益可能来自心脏保护作用。
局限性
- 回顾性研究设计,可能存在未测量混杂因素。
- 甘露醇使用非随机分配,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mannitol, a hyperosmolar solution widely administered for renal protection, may also have cardioprotective effects. Although its benefits in chronic kidney disease patients undergoing vascular surgery are documented, the impact of mannitol on all patients undergoing open abdominal aortic aneurysm (AAA) repair, including patients without chronic kidney disease, remains unclear. This study aimed to evaluate the effect of intraoperative mannitol on mortality, renal protection, and other postoperative outcomes in patients undergoing open AAA repair. METHODS: We conducted a retrospective analysis using data from the Society for Vascular Surgery Vascular Quality Initiative database, covering patients who underwent open AAA repair from 2003 to 2021. The study population was divided into two groups based on intraoperative mannitol use, stratified by proximal clamp location (suprarenal vs infrarenal). Baseline characteristics, comorbidities, and perioperative details were compared between the groups. Postoperative outcomes, including 30-day mortality, renal complications, prolonged length of stay, and 1-year survival, were analyzed using univariable and multivariable logistic regression, Kaplan-Meier survival curves, and Cox regression, adjusting for potential confounders. The multivariable models were adjusted for variables including age, sex, urgency of the procedure, preoperative smoking status, American Society of Anesthesiologists class, clamp duration, estimated blood loss, preoperative creatinine, prior history of congestive heart failure, total procedure time, statin use, and P2Y receptor inhibitor use. RESULTS: Among the 15,961 patients, 8963 (56.2%) received intraoperative mannitol. Mannitol use was associated with lower 30-day mortality rates in both infrarenal (5.4% vs 9.6%; P < .001) and suprarenal clamping (7.3% vs 18.2%; P < .001). In adjusted analyses, mannitol was associated with a significant reduction in 30-day mortality in the suprarenal group (hazard ratio, 0.63; P < .001). Mannitol use did not significantly affect renal complications in either group. However, mannitol use in patients undergoing suprarenal clamping experienced a significant survival benefit regardless of glomerular filtration rate status. CONCLUSIONS: Intraoperative mannitol use during open AAA repair is associated with improved postoperative survival, particularly in patients undergoing suprarenal clamping. Although mannitol does not reduce renal complications significantly, its cardioprotective effects may provide substantial benefits in specific patient subgroups. These findings support the selective use of mannitol in open AAA repair, particularly in high-risk patients.
引用
- Willie-Permor D, Paul Moacdieh M, Straus S, et al. Effect of mannitol administration on outcomes of open abdominal aortic aneurysm repair. J Vasc Surg. 2025. PMID: 40744208. doi:10.1016/j.jvs.2025.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。